Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.

@article{Wiegand2006EarlyMW,
  title={Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.},
  author={J Wiegand and Peter Buggisch and Wulf Otto Boecher and Stefan Zeuzem and Cornelia Maria Gelbmann and Thomas Berg and Wolfgang Kauffmann and Birgit Kallinowski and Markus Cornberg and Elmar Jaeckel and Heiner Wedemeyer and Michael P. Manns},
  journal={Hepatology},
  year={2006},
  volume={43 2},
  pages={250-6}
}
Early treatment of acute hepatitis C with interferon alpha-2b for 24 weeks prevents chronic infection in almost all patients. Because pegylated interferons have replaced conventional interferon in the therapy of chronic hepatitis C, the aim of this study was to analyze the efficacy of an early treatment of acute hepatitis C with peginterferon alpha-2b. Between February 2001 and February 2004, 89 individuals with acute HCV infection were recruited at 53 different centers in Germany. Patients… CONTINUE READING